U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07839455) titled 'Oral and Topical Phytocannabinoids for Psoriasis' on July 28.
Brief Summary: Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of the global population and is frequently associated with psychiatric comorbidities such as anxiety and depression. Although conventional treatments, including topical corticosteroids and biologic agents, may be effective, many patients face challenges related to treatment adherence, adverse effects, and the psychosocial impact of the disease. This open label study aims to investigate the efficacy and acceptability of medicinal cannabis formulations administered orally and topi...